Spots Global Cancer Trial Database for azd2171
Every month we try and update this database with for azd2171 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | NCT01065662 | Endometrial Can... Ovarian Cancer Cervical Cancer Fallopian Tube ... Peritoneal Canc... | temsirolimus cediranib | 18 Years - | Dana-Farber Cancer Institute | |
| Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours | NCT00264004 | Tumors | AZD2171 | 18 Years - | AstraZeneca | |
| Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours | NCT00475956 | Neoplasms | AZD2171 AZD0530 | 18 Years - | AstraZeneca | |
| AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer. | NCT00454805 | Advanced Breast... | AZD2171 Fulvestrant | 18 Years - 130 Years | AstraZeneca | |
| Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases | NCT00501605 | Advanced Solid ... Liver Metastase... | AZD2171 | 18 Years - | AstraZeneca | |
| Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients | NCT00621361 | Lung Cancer | AZD2171 Etoposide Cisplatin | 18 Years - | AstraZeneca | |
| Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma | NCT00942877 | Sarcoma, Alveol... | AZD2171 | - 16 Years | National Institutes of Health Clinical Center (CC) | |
| Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) | NCT00278889 | Colorectal Canc... | AZD2171 5-fluorouracil Leucovorin Oxaliplatin Bevacizumab | 18 Years - | AstraZeneca | |
| A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX | NCT00494221 | Metastatic Colo... | AZD2171 FOLFOX (5-fluor... Placebo Cediran... | 18 Years - | AstraZeneca | |
| Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours | NCT00621725 | Advanced Cancer Hepatic Impairm... | AZD2171 | 18 Years - | AstraZeneca | |
| The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer | NCT00243347 | Carcinoma Non-Small-Cell ... Head and Neck N... | AZD2171 | 18 Years - | AstraZeneca | |
| Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) | NCT00278889 | Colorectal Canc... | AZD2171 5-fluorouracil Leucovorin Oxaliplatin Bevacizumab | 18 Years - | AstraZeneca | |
| AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer. | NCT00454805 | Advanced Breast... | AZD2171 Fulvestrant | 18 Years - 130 Years | AstraZeneca | |
| A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors | NCT00502567 | Advanced Solid ... | AZD2171 FOLFOX Pemetrexed Irinotecan (adm... Docetaxel | 18 Years - | AstraZeneca | |
| A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan | NCT00503477 | Advanced Solid ... | AZD2171 | 20 Years - 75 Years | AstraZeneca | |
| Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial | NCT01160926 | Rectal Cancer | AZD6244 Cediranib (AZD2... | 18 Years - | The Christie NHS Foundation Trust | |
| A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors | NCT00502567 | Advanced Solid ... | AZD2171 FOLFOX Pemetrexed Irinotecan (adm... Docetaxel | 18 Years - | AstraZeneca | |
| Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer | NCT00502060 | Advanced Tumor | AZD2171 ZD1839 | 18 Years - | AstraZeneca | |
| Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours | NCT00621725 | Advanced Cancer Hepatic Impairm... | AZD2171 | 18 Years - | AstraZeneca | |
| An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer | NCT00532194 | Ovarian Cancer | cediranib | 18 Years - | Medical Research Council | |
| A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan | NCT00503477 | Advanced Solid ... | AZD2171 | 20 Years - 75 Years | AstraZeneca | |
| Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients | NCT00621361 | Lung Cancer | AZD2171 Etoposide Cisplatin | 18 Years - | AstraZeneca | |
| The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). | NCT00385203 | Gastrointestina... Soft Tissue Sar... | AZD2171 | 18 Years - | AstraZeneca | |
| AZD2171 to Treat Prostate Cancer | NCT00436956 | Prostate Cancer | Magnetic Resona... AZD2171 Prednisone | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | NCT01065662 | Endometrial Can... Ovarian Cancer Cervical Cancer Fallopian Tube ... Peritoneal Canc... | temsirolimus cediranib | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
